NCT02117427View on ClinicalTrials.gov

TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 27, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

March 20, 2017

Conditions

Chronic Kidney DiseaseEnd Stage Renal Disease

Interventions

BIOLOGICAL

MDGN201 TARGTEPO

Erythropoietin secreted by TARGTEPO transduced with MDGN201

Trial Locations (5)

Unknown

Barzili Medical Center, Ashkelon

Meir Medical Center, Kfar Saba

Medical Center of the Galilee, Nahariya

Tel Aviv Sourasky Medical Center, Tel Aviv

Assaf Harofeh Medical Center, Zrifin

All Listed Sponsors

collaborator

Medgenics Medical Israel Ltd.

INDUSTRY

lead

Aevi Genomic Medicine, LLC, a Cerecor company

INDUSTRY

NCT02117427 - TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD) | Biotech Hunter | Biotech Hunter